Table 2C. Subgroup analyses stratified by some of the baseline characteristics for associations between BRCA2 mutation and overall survival.

	HR	95%CI	Degree of heterogeneity (I2 statistics; %)	P	No. of included Studies
Total	0.57	0.45 to 0.73	50.3	0.016	14
Study quality
Score > 7	0.53	0.40 to 0.70	50.2	0.034	10
≤ 7	0.71	0.41 to 1.21	46.7	0.131	4
Stage of disease
I–IV	0.56	0.43 to 0.74	39.6	0.103	9
II–IV	0.46	0.21 to 0.97	37.2	0.207	2
III–IV	0.64	0.32 to 1.28	64.0	0.062	3
Study design
Cohort	0.56	0.43 to 0.72	48.3	0.030	12
Case-control	0.54	0.13 to 2.14	70.7	0.065	2
Sample size
≥ 200	0.54	0.41 to 0.73	51.4	0.036	9
< 200	0.63	0.38 to 1.04	52.9	0.075	5
Research center
Single	0.52	0.39 to 0.70	24.6	0.224	9
Multicenter	0.65	0.43 to 0.89	71.5	0.007	5
Duration of follow-up Months
> 60	0.59	0.44 to 0.78	55.8	0.016	10
≤ 60	0.52	0.28 to 0.94	45.4	0.139	4
Adequate baseline characteristics adjusted
Yes	0.52	0.40 to 0.68	48.7	0.029	12
No	0.92	0.61 to 1.39	0	0.881	2
Histology
All	0.56	0.44 to 0.72	36.7	0.097	12
High-grade serous	0.54	0.32 to 0.93	79.8	0.002	4
Region
Europe	0.61	0.34 to 1.07	59.0	0.087	3
America/Canada	0.51	0.34 to 0.76	66.5	0.006	7
Asia	0.88	0.44 to 1.75	/	/	1

Abbreviations: HR = hazard ratio; CI = confidence interval.